Special 12/2012

  • BIO-Regions in the European Union

    In an era of tight purse-strings when it comes to collecting capital for long-term projects like drug development, the concentration of know-how in a biotech cluster, incubator or meta-cluster offers bio­tech companies many advantages. Access to a common infrastructure and networks, better visibility for potential corporate and VC investors, and improved access to public funding are only a few of them. Well­­-established biotech hubs also exert an irresistible appeal to national and EU policymakers. They of course are seeking to create high-paying jobs, attract new companies as well as investors and stimulate the socioeconomic growth of entire regions (see p. 38). In this special, EuroBio­techNews presents some of the strategies that European bio-incubators are implementing in their quests to become the next major global hub.

Volume 2014

Volume 2013

Volume 2012

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/magazine/spezial/2012/12.html

Kurszettel

Alle Kurse

TOP

  • ADDEX (CH)4.29 CHF18.51%
  • COSMO PHARMACEUTICALS (CH)179.10 CHF7.76%
  • NEUROVIVE PHARMACEUTICAL AB (S)55.75 SEK6.19%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • BAVARIAN NORDIC (D)15.82 EUR-8.02%

TOP

  • SANTHERA (CH)72.80 CHF137.5%
  • CELLECTIS (F)13.63 EUR103.4%
  • ADDEX (CH)4.29 CHF92.4%

FLOP

  • THROMBOGENICS (B)8.92 EUR-50.4%
  • MERCK KGAA (D)64.16 EUR-50.1%
  • VERONA PHARMA (UK)1.20 GBP-43.4%

TOP

  • SANTHERA (CH)72.80 CHF3576.8%
  • GW PHARMACEUTICALS (UK)444.50 GBP828.4%
  • IXICO (UK)55.50 GBP320.5%

FLOP

  • EVOCUTIS (UK)0.21 GBP-93.3%
  • CYTOS (CH)0.25 CHF-92.8%
  • THROMBOGENICS (B)8.92 EUR-72.4%

No liability assumed, Date: 09.07.2014